---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099336"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T17:06:27.889516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026

## Summary
- Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.
- Cash, equivalents, short-term investments $490.5M at Dec 31, 2025; runway into H2 2029.
- RAP-219 Phase 2a in focal onset seizures met primary endpoints: 77.8% median reduction in clinical seizure frequency.
- Phase 3 program for RAP-219 in FOS accelerated to Q2 2026; open-label safety trial enrolling.
- Entered Tenacia collaboration for Greater China: $20M upfront, up to $308M milestones plus tiered royalties.

## SEC filing metadata
- accession: 0001193125-26-099336
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/0001193125-26-099336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/rapp-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099336
- JSON: https://secwatch.observer/filing/0001193125-26-099336.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099336.txt

## Key facts
- Earnings Releases
  Rapport Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.
  - Period: the quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 10, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/0001193125-26-099336-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.